Guess which ASX 300 healthcare stock just rocketed 20% on BIG earnings growth

Investors are piling into the ASX 300 healthcare stock on Monday. But why?

| More on:
Two lab workers fist pump each other.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

sdf

The S&P/ASX 300 Index (ASX: XKO) is down 0.3% today, but ASX 300 healthcare stock Mayne Pharma Group Ltd (ASX: MYX) is racing in the other direction.

Shares in the Aussie pharmaceuticals company closed on Friday trading for $4.68. During the Monday lunch hour, shares are swapping hands for $5.60 apiece, up 19.7%.

That's enough to lift the Mayne Pharma share price's one-year performance back into the green, up 3.8% over 12 months.

Here's what spurring buying interest in the ASX 300 healthcare stock today.

ASX 300 healthcare stock rockets on strong growth

The Mayne Pharma share price is going ballistic after the company released its preliminary half-year results for the six months ending 31 December.

The company announced that it expected its H1 FY 2025 revenue to be between $210 million and $215 million. This represents a 12% to 14% year-on-year revenue increase.

On the earnings front, Mayne Pharma said it expected to report 1H FY 2025 underlying earnings before interest, taxes, depreciation and amortisation (EBITDA) of $30 million to $32 million. This is up a whopping 275% to 300% from the company's H1 FY 2024 earnings.

The company credited the strong half-year earnings boost to continued growth across its Women's Health portfolio with increased operating leverage. The ASX 300 healthcare stock said its Dermatology unit also saw an improvement in margin, primarily through its product mix.

What did management say?

Commenting on the strong half year for the ASX 300 healthcare stock, Mayne Pharma CEO Shawn Patrick O'Brien said:

We have experienced solid trading conditions in the first half as we execute against our corporate strategies, with robust revenue growth recorded particularly within our Women's Health segment.

We look forward to further updating our investors on our progress and plans at the half year results presentation in late February.

Mayne Pharma is scheduled to release its audited half-year financial results on 26 February.

Management noted that Mayne Pharma's performance since the update provided at its annual general meeting (AGM) on 21 November should be reflected across the entire half and not assumed as a two-month run rate going forward.

As for what investors might expect from the ASX 300 healthcare stock in the second half of FY 2025? The company said it expected to see continued growth, with some seasonal cost impacts from patient payment programs as deductibles reset, along with an increase in promotional expenses for its Women's Health products to drive additional growth.

Motley Fool contributor Bernd Struben has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Man in business suit carries box of personal effects
Healthcare Shares

Monash IVF shares jump 9% as CEO quits after second embryo incident

Two incidents at its clinics have cost this CEO his job.

Read more »

Woman with an amazed expression has her hands and arms out with a laptop in front of her.
Share Gainers

Guess which ASX 200 stock turned $5,000 into $34,264 in just three years!

Investors have been piling into this ASX 200 stock for years, sending the share price soaring.

Read more »

A man holds his head in his hands, despairing at the bad result he's reading on his computer.
Healthcare Shares

Cochlear shares sink 9% on guidance downgrade

Investors haven't responded positively to this update. Let's dig deeper into it.

Read more »

Scientists working in the laboratory and examining results.
Healthcare Shares

Telix shares push higher on investor day update

This radiopharmaceuticals company has grand plans for the future.

Read more »

Shot of a young scientist using a digital tablet while working in a lab.
Healthcare Shares

3 leading ASX healthcare shares with global reach

These 3 healthcare companies are having an outsized impact far beyond local markets.

Read more »

Man looks shocked as he works on laptop on top a skyscraper with stockmarket figures in graphic behind him.
Healthcare Shares

Macquarie tips more than 100% upside for this ASX All Ords healthcare stock

This company could be set to soar.

Read more »

A little boy, soon to be a brother, kisses and holds his mum's pregnant tummy.
Healthcare Shares

Monash IVF shares fall 25% following second embryo incident

Its been a forgettable start to 2025 for Monash IVF shareholders.

Read more »

Shot of two young scientists using a laptop in a laboratory.
Healthcare Shares

Buying CSL shares? Meet your new board director

CSL’s new board director has spent the last 11 years in an executive role at Australia’s $240 billion Future Fund.

Read more »